Eprontia is a Oral Solution in the Human Prescription Drug category. It is labeled and distributed by Azurity Pharmaceuticals, Inc.. The primary component is Topiramate.
| Product ID | 52652-9001_29a0a3e7-a450-4fb1-95af-e4ff74ebe3e5 | 
| NDC | 52652-9001 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Eprontia | 
| Generic Name | Topiramate | 
| Dosage Form | Solution | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2021-12-06 | 
| Marketing Category | NDA / | 
| Application Number | NDA214679 | 
| Labeler Name | Azurity Pharmaceuticals, Inc. | 
| Substance Name | TOPIRAMATE | 
| Active Ingredient Strength | 25 mg/mL | 
| Pharm Classes | Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A4 Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2023-12-31 | 
| Marketing Start Date | 2021-12-06 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 0245-1071 | QUDEXY | Topiramate | 
| 0245-1072 | QUDEXY | Topiramate | 
| 0245-1073 | QUDEXY | Topiramate | 
| 0245-1074 | QUDEXY | Topiramate | 
| 0245-1075 | QUDEXY | Topiramate | 
| 0093-7335 | Topiramate | Topiramate | 
| 0093-7336 | Topiramate | Topiramate | 
| 0615-7562 | Topiramate | Topiramate | 
| 0615-7563 | Topiramate | Topiramate | 
| 0615-7564 | Topiramate | Topiramate | 
| 0615-7565 | Topiramate | Topiramate | 
| 0615-8138 | Topiramate | Topiramate | 
| 0615-8139 | Topiramate | Topiramate | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  EPRONTIA  90690878  not registered Live/Pending | Azurity Pharmaceuticals, Inc. 2021-05-05 |